Aspen Pharmacare plans to start supplying Johnson & Johnson Covid-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday. Stephen Saad told Reuters in an interview that the technology transfer from J&J has “gone very well and we are now committing commercial supply in our financial year.” The company’s financial year ends in June. The company has committed 300 million Covid-19 vaccine doses, however the final amount that will be manufactured will depend on demand from J&J, he said. Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process. You will be redirected to a checkout page.
To view all features and options, click here. A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.